Combination Immunotherapy and TKI in Metastatic Refractory Thyroid Cancer, a Case Series

Patients with metastatic thyroid cancer (mTC) have limited options for effective therapies. Tyrosine kinase inhibitors (TKIs) remain the mainstay of treatment, often at the expense of significant systemic side effects without a proven survival benefit. The use of immunotherapy has revolutionized the treatment of cancer, however, its specific utility in mTC is not yet known.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Non-squamous Cell Malignancies of the Head and Neck: thyroid, sarcomas, skin cancers, salivary gland and sinus cancers Source Type: research